Covered recipient · General Payments record
ERIC L SIMPSON
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$216,670.40
237 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $142,320.54 | 30 |
| Travel and Lodging | $51,483.58 | 101 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,571.80 | 30 |
| Food and Beverage | $2,149.48 | 75 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,145.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Eli Lilly and Company | $49,728.87 | 60 |
| PFIZER INC. | $44,305.43 | 24 |
| SANOFI-AVENTIS U.S. LLC | $42,460.34 | 29 |
| Regeneron Healthcare Solutions, Inc. | $19,237.62 | 11 |
| GENZYME CORPORATION | $18,509.56 | 14 |
| ABBVIE INC. | $9,534.93 | 25 |
| LEO Pharma AS | $9,470.52 | 28 |
| Lilly USA, LLC | $7,230.30 | 8 |
| DERMIRA, INC. | $7,093.23 | 21 |
| UCB SA | $2,799.73 | 12 |
| Bausch Health US, LLC | $2,194.87 | 2 |
| LEO Pharma Inc. | $1,965.00 | 1 |
| Novartis Pharmaceuticals Corporation | $1,440.00 | 1 |
| Regeneron Pharmaceuticals, Inc. | $700.00 | 1 |
Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ERIC L SIMPSON
NPI 1972511426 · CMS profile ID 362051
Allopathic & Osteopathic Physicians / Dermatology
PORTLAND, OR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ERIC L SIMPSON, NPI 1972511426, CMS profile ID 362051. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ERIC L SIMPSON, NPI 1972511426, CMS profile ID 362051. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ERIC L SIMPSON, NPI 1972511426, CMS profile ID 362051, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972511426?year=2019&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
237 matching records · $216,670.40 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 237.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $131.87 | 09/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009073 | CMS |
| Eli Lilly and Company | $2.21 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009209 | CMS |
| Eli Lilly and Company | $13.79 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009211 | CMS |
| Eli Lilly and Company | $51.24 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009213 | CMS |
| Eli Lilly and Company | $2.21 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009215 | CMS |
| Eli Lilly and Company | $13.79 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009217 | CMS |
| Eli Lilly and Company | $9.23 | 09/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009219 | CMS |
| Eli Lilly and Company | $43.13 | 09/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009221 | CMS |
| Eli Lilly and Company | $9.23 | 09/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009223 | CMS |
| Eli Lilly and Company | $2.24 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009225 | CMS |
| Eli Lilly and Company | $14.02 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009559 | CMS |
| Eli Lilly and Company | $9.23 | 09/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009561 | CMS |
| Eli Lilly and Company | $9.23 | 09/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009563 | CMS |
| Eli Lilly and Company | $13.79 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 709009565 | CMS |
| Eli Lilly and Company | $8,805.13 | 09/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657794595 | CMS |
| SANOFI-AVENTIS U.S. LLC | $172.38 | 09/13/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207473 | CMS |
| SANOFI-AVENTIS U.S. LLC | $205.70 | 09/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207477 | CMS |
| SANOFI-AVENTIS U.S. LLC | $318.00 | 08/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207493 | CMS |
| SANOFI-AVENTIS U.S. LLC | $318.00 | 08/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207495 | CMS |
| SANOFI-AVENTIS U.S. LLC | $318.00 | 08/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207499 | CMS |
| PFIZER INC. | $330.00 | 08/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673786475 | CMS |
| PFIZER INC. | $330.00 | 08/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673786767 | CMS |
| PFIZER INC. | $149.95 | 08/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672982403 | CMS |
| PFIZER INC. | $330.00 | 08/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673786477 | CMS |
| SANOFI-AVENTIS U.S. LLC | $278.31 | 08/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207481 | CMS |
| PFIZER INC. | $1,250.00 | 08/14/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672982409 | CMS |
| PFIZER INC. | $7,750.00 | 08/05/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672982397 | CMS |
| SANOFI-AVENTIS U.S. LLC | $278.31 | 08/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207485 | CMS |
| SANOFI-AVENTIS U.S. LLC | $278.31 | 08/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694207489 | CMS |
| PFIZER INC. | $243.28 | 07/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672599999 | CMS |
| PFIZER INC. | $6,690.03 | 07/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672600003 | CMS |
| PFIZER INC. | $334.16 | 07/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672600121 | CMS |
| PFIZER INC. | $105.91 | 07/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672600125 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5,520.00 | 06/05/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477815 | CMS |
| Regeneron Healthcare Solutions, Inc. | $47.88 | 06/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477817 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.32 | 06/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477819 | CMS |
| SANOFI-AVENTIS U.S. LLC | $354.90 | 05/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694056541 | CMS |
| GENZYME CORPORATION | $2,808.00 | 05/22/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694209065 | CMS |
| SANOFI-AVENTIS U.S. LLC | $317.90 | 05/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694056657 | CMS |
| LEO Pharma Inc. | $1,965.00 | 05/08/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687272227 | CMS |
| UCB SA | $13.70 | 05/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681635941 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5,865.00 | 05/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477813 | CMS |
| Regeneron Healthcare Solutions, Inc. | $5,520.00 | 04/30/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477811 | CMS |
| Regeneron Healthcare Solutions, Inc. | $82.13 | 04/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477807 | CMS |
| Regeneron Healthcare Solutions, Inc. | $75.71 | 04/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477809 | CMS |
| SANOFI-AVENTIS U.S. LLC | $26.96 | 04/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694016293 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.25 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477803 | CMS |
| Regeneron Healthcare Solutions, Inc. | $626.00 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673477805 | CMS |
| Eli Lilly and Company | $26.56 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657791359 | CMS |
| Eli Lilly and Company | $99.00 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657798137 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $39,904.20 | 31 |
| PY2025 | Principal investigator | $341,052.93 | 172 |
| PY2024 | Recipient | $63,467.28 | 89 |
| PY2024 | Principal investigator | $366,180.88 | 395 |
| PY2023 | Recipient | $58,323.42 | 64 |
| PY2023 | Principal investigator | $675,749.91 | 291 |
| PY2022 | Recipient | $75,036.89 | 96 |
| PY2022 | Principal investigator | $506,268.96 | 125 |
| PY2021 | Recipient | $70,599.39 | 105 |
| PY2021 | Principal investigator | $519,590.85 | 149 |
| PY2020 | Recipient | $61,672.35 | 73 |
| PY2020 | Principal investigator | $340,023.80 | 102 |
| PY2019 | Recipient | $50,336.57 | 71 |
| PY2019 | Principal investigator | $653,736.00 | 79 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
203 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 12/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133783 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 12/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133785 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 12/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133787 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 12/19/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133779 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 12/19/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133781 |
| Principal investigator 1 | ABBVIE INC. | $12,735.52 | 12/16/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202417947 |
| Principal investigator 1 | ABBVIE INC. | $1,712.50 | 12/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417931 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,328.00 | 12/08/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092288 |
| Principal investigator 1 | ABBVIE INC. | $11,002.03 | 12/04/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202417919 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,644.38 | 12/04/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133741 |
| Recipient | GENZYME CORPORATION | $250.00 | 12/02/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226117226 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,142.00 | 12/02/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092293 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $353.57 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122691 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 12/01/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133729 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 12/01/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133731 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 12/01/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133733 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 12/01/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133735 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $233.00 | 11/14/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133723 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $184.86 | 11/07/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133719 |
| Recipient | PFIZER INC. | $1,400.00 | 11/06/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727017 |
| Recipient | PFIZER INC. | $1,400.00 | 11/06/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727725 |
| Principal investigator 1 | ABBVIE INC. | $3,325.00 | 10/28/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $246.48 | 10/23/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133711 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 10/20/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133709 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,234.00 | 10/20/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092277 |
| Recipient | GENZYME CORPORATION | $500.00 | 10/15/2025 | Covered Recipient Physician | A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226117210 |
| Principal investigator 1 | ABBVIE INC. | $1,250.13 | 10/09/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417845 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,370.00 | 10/06/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092247 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,330.98 | 10/03/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133701 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,881.05 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122687 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $3,426.80 | 10/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122689 |
| Recipient | Amgen Inc. | $2,030.55 | 09/22/2025 | Covered Recipient Physician | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) | No dispute reported | 06/30/2026 | 1246637314 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,947.45 | 09/22/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092233 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 09/18/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133699 |
| Principal investigator 1 | ABBVIE INC. | $1,027.50 | 09/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417771 |
| Recipient | PFIZER INC. | $940.00 | 09/04/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727805 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.72 | 08/26/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133697 |
| Recipient | PFIZER INC. | $3,200.00 | 08/25/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726718 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,923.00 | 08/25/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 08/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133695 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 08/20/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133693 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,498.28 | 07/31/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $308.10 | 07/31/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133685 |
| Recipient | PFIZER INC. | $3,200.00 | 07/30/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727683 |
| Recipient | PFIZER INC. | $3,200.00 | 07/30/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727735 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133623 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133625 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.35 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133627 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $34.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133629 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.10 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133631 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $304.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133633 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.80 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133635 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.70 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133637 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.35 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133639 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $34.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133641 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.10 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133643 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $304.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133645 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.80 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133647 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.70 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133649 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133651 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133653 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $248.70 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133655 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133657 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133659 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133661 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133663 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133665 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $277.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133667 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $219.45 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $331.35 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.10 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133675 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $304.95 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $214.80 | 07/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133679 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,527.00 | 07/14/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092131 |
| Principal investigator 1 | ABBVIE INC. | $450.00 | 07/10/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417686 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,114.46 | 07/10/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133621 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,031.00 | 07/02/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092137 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,425.00 | 07/02/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092149 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,165.00 | 07/02/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092155 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/18/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133601 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $398.75 | 06/18/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133603 |
| Principal investigator 1 | ABBVIE INC. | $7,467.50 | 06/17/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417661 |
| Principal investigator 1 | ABBVIE INC. | $1,986.50 | 06/17/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417666 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/17/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226117201 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/17/2025 | Covered Recipient Physician | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226117206 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $115.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133479 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $115.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $115.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $116.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $116.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133487 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $116.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133489 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $124.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133491 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $234.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133493 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133495 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133499 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133501 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $300.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133503 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $308.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $308.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133507 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $308.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $332.50 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $941.43 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $984.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $984.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133517 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $997.50 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133519 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133523 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $45.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,995.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $46.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,660.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,100.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $52.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $54.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $54.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $54.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $55.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.19 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.19 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $57.19 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $62.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $78.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $86.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $86.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $86.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133579 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $86.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133581 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $86.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $86.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133585 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $92.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $92.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133591 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $92.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133593 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133595 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133597 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $104.00 | 06/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133599 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $184.86 | 06/05/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,750.00 | 06/05/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133473 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 06/05/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133475 |
| Principal investigator 1 | ABBVIE INC. | $359.63 | 06/03/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417581 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $640.68 | 06/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122685 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $369.72 | 05/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133453 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,000.00 | 05/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133455 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $600.00 | 05/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 05/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133459 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $800.00 | 05/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133461 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,200.00 | 05/22/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133463 |
| Recipient | PFIZER INC. | $330.00 | 05/08/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228719533 |
| Recipient | PFIZER INC. | $330.00 | 05/07/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760993 |
| Principal investigator 1 | ABBVIE INC. | $1,621.90 | 05/06/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417542 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $247.50 | 05/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122683 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $29,700.00 | 04/28/2025 | Non-covered Recipient Entity OREGON HEALTH SCIENCE UNIV PHS | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment | No dispute reported | 06/30/2026 | 1226092143 |
| Recipient | PFIZER INC. | $3,200.00 | 04/26/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228752596 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,243.02 | 04/15/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133445 |
| Principal investigator 1 | ABBVIE INC. | $800.00 | 04/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417518 |
| Principal investigator 1 | ABBVIE INC. | $3,325.00 | 04/10/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417512 |
| Principal investigator 1 | ABBVIE INC. | $11,520.00 | 04/03/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202417491 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $668.22 | 04/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122677 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2,600.70 | 04/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122679 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $741.07 | 04/01/2025 | Covered Recipient Physician | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122681 |
| Principal investigator 1 | Eli Lilly and Company | $7,988.40 | 03/27/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187874891 |
| Principal investigator 1 | Incyte Corporation | $171.63 | 03/27/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240487746 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $184.86 | 03/19/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133433 |
| Principal investigator 1 | ABBVIE INC. | $19,338.10 | 03/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | M24-601 - A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202417452 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $246.48 | 03/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133431 |
| Principal investigator 1 | ABBVIE INC. | $2,414.64 | 03/07/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417448 |
| Recipient | GENZYME CORPORATION | $500.00 | 03/07/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226117217 |
| Recipient | GENZYME CORPORATION | $250.00 | 03/07/2025 | Covered Recipient Physician | An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226117221 |
| Principal investigator 1 | ABBVIE INC. | $296.55 | 03/06/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417437 |
| Principal investigator 1 | Incyte Corporation | $6,900.00 | 03/05/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240487766 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $2,553.75 | 03/01/2025 | Covered Recipient Physician | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122667 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,168.33 | 03/01/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122669 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $190.38 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122671 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,021.50 | 03/01/2025 | Covered Recipient Physician | A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122673 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $928.64 | 03/01/2025 | Covered Recipient Physician | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184122675 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,875.00 | 02/24/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133419 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $308.10 | 02/18/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133415 |
| Principal investigator 1 | ABBVIE INC. | $1,712.50 | 02/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202417416 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,229.19 | 02/11/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133411 |
| Principal investigator 1 | Incyte Corporation | $2,931.32 | 02/05/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240487760 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $76,991.29 | 02/05/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | EFFECTS OF INTERLEUKIN (IL)-4/IL-13 BLOCKADE ON THE STRUCTURE AND FUNCTION OF CUTANEOUS SENSORY NERVES | No dispute reported | 06/30/2026 | 1184133405 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $1,061.46 | 02/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184122665 |
| Recipient | PFIZER INC. | $940.00 | 01/30/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760472 |
| Principal investigator 1 | Incyte Corporation | $2,335.71 | 01/28/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240487773 |
| Principal investigator 1 | Incyte Corporation | $845.51 | 01/23/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240487741 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $744.74 | 01/21/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133395 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $776.40 | 01/17/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $665.00 | 01/13/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133389 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $665.00 | 01/13/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133391 |
| Principal investigator 1 | ABBVIE INC. | $450.00 | 01/08/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202417360 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $123.24 | 01/07/2025 | Covered Recipient Teaching Hospital OHSU HOSPITAL AND CLINICS | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1184133387 |
| Principal investigator 1 | Incyte Corporation | $1,600.00 | 01/04/2025 | Covered Recipient Teaching Hospital Ohsu Hospital And Clinics | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240487752 |